Understanding mortality in multiple myeloma: findings of a european retrospective chart review
Objectives This study aimed to provide real-world data on the characteristics and treatment of patients with multiple myeloma (MM) at the time of death. Methods The study was a retrospective patient chart review across France, Germany, Italy, Spain and the UK during 2016, and included patients who h...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 May 2019
|
| In: |
European journal of haematology
Year: 2019, Jahrgang: 103, Heft: 2, Pages: 107-115 |
| ISSN: | 1600-0609 |
| DOI: | 10.1111/ejh.13264 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1111/ejh.13264 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13264 
|
| Verfasserangaben: | Mohamad Mohty, Michele Cavo, Leah Fink, Sebastian Gonzalez‐McQuire, Henri Leleu, Maria-Victoria Mateos, Marc S. Raab, Paul Schoen, Kwee Yong |
| Zusammenfassung: | Objectives This study aimed to provide real-world data on the characteristics and treatment of patients with multiple myeloma (MM) at the time of death. Methods The study was a retrospective patient chart review across France, Germany, Italy, Spain and the UK during 2016, and included patients who had died in the 3 months before the index date. Results Data from 786 patients were reviewed. At the time of death, 37% of patients were receiving active treatment, 12% were in a treatment-free interval and 51% were receiving only supportive care. Death before and during active first-line treatment was not uncommon (6% and 24% of patients, respectively) but these deaths were often not solely due to disease progression; factors such as renal failure and infection frequently played a role (in 30% and 20% of patients at first-line, respectively). Most deaths at later lines were due to progressive disease. Cox model results suggested that early deaths were associated with advanced disease stage, high-risk cytogenetics and poor response and relapse profiles. Conclusions These real-world data could be used to help develop strategies for improving survival in patients with MM and to support management tailored to the stage of disease. |
|---|---|
| Beschreibung: | Gesehen am TT.MM.JJJ |
| Beschreibung: | Online Resource |
| ISSN: | 1600-0609 |
| DOI: | 10.1111/ejh.13264 |